Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine

Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine We have investigated whether poly(I:C) Toll-like receptor 3 (TLR3) and resiquimod Toll-like receptor 7 (TLR7) agonists can serve as vaccine adjuvants and promote the efficiency of therapeutic DNA vaccination against tumors expressing the human papilloma virus 16 (HPV-16) E7 protein. For this purpose, C57BL/6 mice were inoculated with 2 × 10 5 TC-1 cells, and they were then immunized with HPV-16 E7 DNA vaccine alone or with 50 μg of resiquimod or poly(I:C) individually. We found that poly(I:C) and resiquimod could induce more antigen-specific lymphocyte proliferation and cytolytic activity compared to vaccination with E7 DNA alone. While E7 DNA had no significant inhibitory effect on tumor growth, co-administration of poly(I:C) and resiquimod with E7 DNA induced significant tumor regression. Peripheral and local cytokine assays demonstrated that co-administration of poly(I:C) and resiquimod with E7 DNA induced circulating antigen-specific IFN-γ and nonspecific intratumoral IL-12. TLR3 and TLR7 agonists can be used to enhance the immune response to DNA vaccine immunogens. Taken together, these data indicate that combined vaccination with DNA encoding HPV-16 E7 plus TLR agonists provides a strategy for improving the efficacy of a vaccine as a possible immunotherapeutic strategy for cervical cancer. Archives of Virology Springer Journals

Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine

Loading next page...
Springer Vienna
Copyright © 2014 by Springer-Verlag Wien
Biomedicine; Virology; Medical Microbiology; Infectious Diseases
Publisher site
See Article on Publisher Site


  • Toll-like receptor agonists in cancer therapy
    Adams, S
  • Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod
    Gibson, SJ; Lindh, JM; Riter, TR; Gleason, RM; Rogers, LM; Fuller, AE; Oesterich, JL; Gorden, KB; Qiu, X; McKane, SW; Noelle, RJ; Miller, RL; Kedl, RM; Fitzgerald-Bocarsly, P; Tomai, MA; Vasilakos, JP
  • Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
    Longhi, MP; Trumpfheller, C; Idoyaga, J; Caskey, M; Matos, I; Kluger, C; Salazar, AM; Colonna, M; Steinman, RM
  • Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity
    Trumpfheller, C; Longhi, MP; Caskey, M; Idoyaga, J; Bozzacco, L; Keler, T; Schlesinger, SJ; Steinman, RM

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial